Anders Gram, Ph.D., appointed Chief Production and Global Supply Chain Officer and Larry Bell, M.D., appointed Global Head of Regulatory Affairs and Pharmacovigilance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pronutria Biosciences, Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, today announced the appointment of Anders Gram, Ph.D., as Senior Vice President and Chief Production and Global Supply Chain Officer and Larry Bell, M.D., as Senior Vice President and Global Head of Regulatory Affairs and Pharmacovigilance.
“We are thrilled to welcome Anders and Larry to Pronutria’s leadership team, and look forward to their immediate and significant contributions as we accelerate development of our novel class of precision-based amino acid therapeutics,” said Dr. Peter Mueller, President of R&D and Chief Scientific Officer at Pronutria Biosciences. “They bring a wealth of relevant experience and expertise, including proven successes in advancing new modalities and platforms, and navigating the manufacturing and regulatory complexities associated with developing and commercializing breakthrough therapies and nutritional products.”
Prior to joining Pronutria Biosciences, Dr. Gram was Vice President of Operations at Ferrosan Medical Devices where he was responsible for the company’s manufacturing and supply-chain operations. He has more than 25 years of experience in the biotechnology, pharmaceutical and medical device industries with a focus on process and product development, operational improvements and supply chain and manufacturing. Dr. Gram brings expertise in protein production from his 22 years at Novozymes, a world leader in industrial enzymes, where he served in a number of roles including General Manager, Vice President of Pharmaceutical Manufacturing and Vice President of Development. He received his Ph.D. from the Danish Technical University.
“I am very excited to join the Pronutria team and help build the manufacturing and supply chain infrastructure required to advance the tremendous potential of this company to address numerous disorders with its novel platform and amino acid-based approach,” said Dr. Gram. “I look forward to working closely with my fellow colleagues to further solidify Pronutria’s role as a pioneer in this emerging and highly promising area of biology.”
Dr. Bell was previously Vice President, Regulatory and Pharmacovigilance at Prosensa, responsible for developing and implementing regulatory strategies for RNA-modulating therapeutics. During his more than 20 year tenure in the pharmaceutical industry, Dr. Bell served as Global Head of Regulatory Affairs, Patient Safety, Epidemiology and Risk Management as well as Regulatory Operations at Aventis, Amgen and GE Healthcare, and led several therapeutic area regulatory groups at Merck and Bristol-Myers Squibb. He has an unprecedented track record of linking clinical development with global regulatory strategies to optimize successful regulatory approvals. He has direct or indirect experience with more than 100 Investigational New Drug (IND) Applications, New Drug Applications (NDA), Marketing Authorization Applications (MAA) and numerous drug approvals and postmarket approvals worldwide. Dr. Bell is Board certified in Internal Medicine and Board eligible in Clinical Nutrition. He earned his M.D. from the University of Texas Medical Branch and completed a residency in internal medicine at the University of California-Davis.
“Pronutria is at the forefront of developing first in class, novel amino acid therapeutics for patients facing serious conditions who currently have few or no effective treatment options,” said Dr. Bell. “This new class of products and the company’s unprecedented knowledge of amino acid imbalances present a unique opportunity to engage and collaborate with regulators to determine the most appropriate path forward.”
About Pronutria Biosciences
Amino acid biology is fundamental to life, regulating biological pathways critical to health. A variety of conditions occur when amino acid pathways become dysregulated. Pronutria Biosciences is developing first-in-class solutions to these conditions with a focus on amino acid biology. Using insights from a clinically validated body of evidence, we are pioneering new nutritional and therapeutic modalities: amino acid biologics. This novel approach allows us to precisely target biology that was previously inaccessible, providing a unique opportunity to address a variety of serious nutritional and medical conditions, such as muscle, metabolic, neurological, liver disorders, and inborn errors of metabolism. Founded by Flagship VentureLabs, privately-held Pronutria Biosciences is based in Cambridge, MA. For more information, please visit www.pronutriabio.com.